Lonza to expand antibody-drug conjugate manufacturing capacity in Switzerland

07:01 AM | January 8, 2013 | Deepti Ramesh

Lonza says it plans to invest 14 million Swiss francs ($15 million) to expand antibody-drug conjugate (ADC) manufacturing capacity at the company’s site at Visp, Switzerland. Oncology therapeutics...